Cargando…
Combining Potent Statin Therapy with Other Drugs to Optimize Simultaneous Cardiovascular and Metabolic Benefits while Minimizing Adverse Events
Hypercholesterolemia and hypertension are among the most important risk factors for cardiovascular (CV) disease. They are also important contributors to metabolic diseases including diabetes that further increase CV risk. Updated guidelines emphasize targeted reduction of overall CV risks but do not...
Autores principales: | Koh, Kwang Kon, Sakuma, Ichiro, Shimada, Kazunori, Hayashi, Toshio, Quon, Michael J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Cardiology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537141/ https://www.ncbi.nlm.nih.gov/pubmed/28765731 http://dx.doi.org/10.4070/kcj.2016.0406 |
Ejemplares similares
-
Angiotensin converting enzyme inhibitors remain the first treatment of choice
por: Oh, Pyung Chun, et al.
Publicado: (2016) -
Combination Pravastatin and Valsartan Treatment Has Additive Beneficial Effects to Simultaneously Improve Both Metabolic and Cardiovascular Phenotypes Beyond That of Monotherapy With Either Drug in Patients With Primary Hypercholesterolemia
por: Koh, Kwang Kon, et al.
Publicado: (2013) -
Creation and Validation of an EMR-based Algorithm for Identifying Major Adverse Cardiac Events while on Statins
por: Wei, Wei-Qi, et al.
Publicado: (2014) -
Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering?
por: Deanfield, John E., et al.
Publicado: (2010) -
Chronic Sleep Restriction While Minimizing Circadian Disruption Does Not Adversely Affect Glucose Tolerance
por: Yuan, Robin K., et al.
Publicado: (2021)